<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease in children: Overview of management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease in children: Overview of management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease in children: Overview of management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tarak Srivastava, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley A Warady, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) refers to a state of irreversible kidney damage and/or reduction of kidney function that is associated with progressive loss of kidney function over time.</p><p>An overview of the management of CKD in children will be reviewed here. The etiology, epidemiology, natural course, presentation, and evaluation of CKD in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course"</a> and  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>CKD is defined as the presence of structural or functional kidney damage that persists over a minimum period of three months. Functional damage is characterized by sustained reduction of estimated glomerular filtration rate (GFR), persistent elevation of urinary protein excretion, or both.</p><p>Clinical practice guidelines from Kidney Disease: Improving Global Outcomes (KDIGO) include the following criteria for diagnosis and staging of pediatric CKD [<a href="#rid1">1</a>]. The are the standard criteria used in clinical practice, research, and public health in the care of children with CKD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The KDIGO diagnosis of pediatric CKD is based on fulfilling <strong>one</strong> of the following clinical criteria [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GFR of less than 60 mL/min per 1.73 m<sup>2</sup> for greater than three months with implications for health regardless of whether other CKD markers are present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GFR greater than 60 mL/min per 1.73 m<sup>2</sup> that is accompanied by evidence of structural damage or other markers of functional kidney abnormalities including proteinuria, albuminuria, renal tubular disorders, or pathologic abnormalities detected by histology or inferred by imaging. This category also includes patients with functioning kidney transplants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The KDIGO CKD staging for children older than two years of age stratifies the risk for progression of CKD and its complications based on GFR and is used to guide management  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>G1 – Normal GFR (≥90 mL/min per 1.73 m<sup>2</sup>)</p><p class="bulletIndent2"><span class="glyph">•</span>G2 – GFR between 60 and 89 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>G3a – GFR between 45 and 59 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>G3b – GFR between 30 and 44 mL/min per 1.73m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>G4 – GFR between 15 and 29 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>G5 – GFR &lt;15 mL/min per 1.73 m<sup>2</sup>, also referred to as kidney failure [<a href="#rid2">2</a>]</p><p></p><p class="bulletIndent1">Children under two years of age do not fit within the above classification system, because they normally have a low GFR even when corrected for body surface area. In these patients, calculated GFR based on serum creatinine can be compared with normative age-appropriate values to detect kidney impairment  (<a class="graphic graphic_table graphicRef116099" href="/d/graphic/116099.html" rel="external">table 2</a>). The KDIGO guideline suggests that a GFR value more than one standard deviation below the mean should raise concern and prompt more intensive monitoring [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Equations that can be used to estimate GFR in children and young adults (1 to 25 years) are based on serum creatinine and cystatin C values, respectively [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Estimated glomerular filtration rate'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">MANAGEMENT APPROACH BY STAGE OF CHRONIC KIDNEY DISEASE</span><span class="headingEndMark"> — </span>The general management of the patient with CKD includes the following components:</p><p class="bulletIndent1"><span class="glyph">●</span>Routine health maintenance</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent or slow the progression of kidney disease</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent or treat the complications of CKD</p><p class="bulletIndent1"><span class="glyph">●</span>Preparation for kidney replacement therapy (KRT) when approaching kidney failure (stage G5)</p><p></p><p>Our practice is consistent with recommendations in the KDIGO Clinical Practice Guideline and the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [<a href="#rid1">1,4</a>]. Routine health care is provided to all children with CKD. The timing of implementation of the other components of care vary primarily based on the severity of CKD (see  <a class="medical medical_society_guidelines" href="/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early asymptomatic CKD: Stages G1 and G2</strong> – Children with stages G1 and G2 disease are asymptomatic and should be closely followed for deterioration of kidney function. Although not frequent, metabolic derangements may be seen in stage G1 and G2. For these children, there may be an opportunity to treat any reversible cause of kidney dysfunction and prevent or slow the progression of CKD. Educational outreach is initiated so that the child and family can understand and implement care to avoid risk factors that can accelerate the progression of CKD (eg, avoidance of nephrotoxic drugs, recurrent infections, dehydration, obesity, smoking, and use of illicit drugs in adolescents) and incorporate measures (eg, strict blood pressure [BP] control and/ or reducing proteinuria) that may slow the process. (See <a class="local">'Prevent or slow progression of kidney disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate CKD: Stages G3a and G3b</strong> – Children who progress to stages G3a and G3b may begin to display CKD-associated complications. These include disorders of fluid and electrolytes, anemia, hypertension, dyslipidemia, endocrine abnormalities, growth impairment, mineral and bone disorder, and decreased clearance of substances normally excreted from the body by the kidney (uremia). In these patients, management is focused on preventing and treating these complications. In addition, avoidance of risk factors, as outlined above, should be maintained to slow CKD progression. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe CKD and kidney failure: Stages G4 and G5</strong> – Patients who continue to have progressive disease need to be identified well in advance of the time that KRT is required so that adequate preparation and education can be provided to both the patient and family. The preparation for KRT generally starts with stage G4 CKD when glomerular filtration rate (GFR) falls below 30 mL/min per 1.73 m<sup>2</sup>. (See <a class="local">'Preparation for kidney failure'</a> below.)</p><p></p><p class="headingAnchor" id="H1541096337"><span class="h1">ROUTINE HEALTH MAINTENANCE</span><span class="headingEndMark"> — </span>As CKD progresses, children are at increased risk for developing complications such as poor growth, elevated blood pressure (BP), increased cardiovascular risk (eg, dyslipidemia), anemia, vitamin D deficiency, and fluid and electrolyte abnormalities (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications"</a>). As a result, routine health maintenance, in addition to the care provided normally to all children, requires more intense monitoring of kidney function, growth, and nutritional status, with intervention as needed and screening for associated complications as CKD progresses [<a href="#rid4">4-15</a>].</p><p class="headingAnchor" id="H2094656178"><span class="h2">Growth and nutrition</span><span class="headingEndMark"> — </span>Appetite and nutritional intake decrease with progression of CKD in children [<a href="#rid16">16,17</a>]. As a result, malnutrition is common in children with CKD because of poor appetite; decreased intestinal absorption of nutrients; and metabolic acidosis affecting physical growth, neurocognitive development, and overall health status (ie, fragility) [<a href="#rid18">18</a>]. Weight loss primarily occurs when the glomerular filtration rate (GFR) decreases to &lt;35 mL/min per 1.73 m<sup>2</sup>, and this weight loss is associated with a higher risk for kidney failure [<a href="#rid19">19</a>].</p><p>A protocol for monitoring growth and nutrition in children with CKD is outlined in the table  (<a class="graphic graphic_table graphicRef52366" href="/d/graphic/52366.html" rel="external">table 3</a>), consistent with recommendations from the 2008 KDOQI and Pediatric Renal Nutrition Taskforce (PRNT) [<a href="#rid20">20-27</a>]. The assessments are more frequent for younger children and those with severe impairment of kidney function regardless of age (ie, stages G4 and G5).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth</strong> – For all children, measure height and weight at each visit. For children &lt;3 years, also monitor head circumference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional assessments</strong> – At each scheduled visit, assess dietary intake using either a three-day diet record or three 24-hour dietary recalls.</p><p></p><p class="bulletIndent1">Nutritional therapy based on growth parameters is developed for each child with CKD and should ideally be coordinated by a dietician with expertise in pediatrics and renal nutrition. Nutritional management should address the energy, protein, vitamin, mineral, and electrolyte needs of the individual patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Energy</strong> – The initial prescribed energy (calorie) intake for children with CKD is similar to that for healthy children of the same chronologic age, which can be calculated from prediction equations  (<a class="graphic graphic_table graphicRef56276" href="/d/graphic/56276.html" rel="external">table 4</a>) or found in summary tables [<a href="#rid21">21,28</a>] (see  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children", section on 'Energy and macronutrient balance'</a>). The recommendations of KDOQI are expressed in terms of the dietary reference intakes (DRIs). Recommendations from the PRNT are expressed in terms of the suggested dietary intake, which takes into consideration the range of published values. For children with suboptimal growth, the target should be adjusted toward the higher end of the suggested energy intake.</p><p></p><p class="bulletIndent2">Further supplementation should be considered when the initial intake fails to meet the child's estimated energy requirement and they are not achieving expected rates of weight gain and/or growth. Although supplementation by the oral route is preferred, one may have to resort to tube feedings with a gastrostomy, transpyloric tube, or nasogastric tube to ensure adequate energy intake [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/d/html/15643.html" rel="external">"Overview of enteral nutrition in infants and children"</a>). A trial of intradialytic parenteral nutrition may be considered in children undergoing chronic hemodialysis therapy. (See  <a class="medical medical_review" href="/d/html/14562.html" rel="external">"Hemodialysis for children with chronic kidney disease", section on 'Inadequate nutrition'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Protein</strong> – Targets for protein intake suggested by KDOQI are  (<a class="graphic graphic_table graphicRef81506" href="/d/graphic/81506.html" rel="external">table 5</a>) [<a href="#rid21">21,28</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CKD stage G3 – 100 to 140 percent of the DRI</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CKD stages G4 and G5 – 100 to 120 percent of the DRI</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients on peritoneal dialysis – Protein intake should be higher (additional average 0.15 to 0.3 g/kg per day) to compensate for dialytic protein loss</p><p></p><p class="bulletIndent2">The PRNT recommendations are similar, except for the suggested dietary intake as the reference value for protein requirement. Protein supplementation should be considered if the oral and/or enteral protein intake is inadequate [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent2">Protein restriction is not recommended in children, as it has not been shown to influence the decrease in kidney function in children with CKD and may impair growth [<a href="#rid29">29-31</a>]. (See <a class="local">'Other interventions with insufficient evidence'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamins and minerals</strong> – Children with CKD should receive 100 percent of the DRIs for the following nutrients [<a href="#rid28">28</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamins – Thiamine (B1); riboflavin (B2); pyridoxine (B6); vitamins B12, A, C, E, K; and <a class="drug drug_pediatric" data-topicid="13322" href="/d/drug information/13322.html" rel="external">folic acid</a>  (<a class="graphic graphic_table graphicRef69963" href="/d/graphic/69963.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef81151" href="/d/graphic/81151.html" rel="external">table 7</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Minerals – Copper and zinc</p><p></p><p class="bulletIndent2">Special considerations are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamin D – Vitamin D deficiency is common in children with CKD, and the formulation of vitamin D supplementation depends on the severity of kidney function, as discussed separately. (See  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Vitamin D deficiency'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamin A – In children with advanced CKD (ie, stage G5), the loss of kidney clearance of vitamin A metabolites places them at risk for developing hypervitaminosis A. These children should receive a water-soluble vitamin supplement that includes vitamin A only if they have very low dietary intake of vitamin A.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamins E and K – There are no formal recommendations regarding supplementation of vitamin E and K in children and adults with CKD or those undergoing dialysis, due to the lack of data. However, if a child with CKD has an underlying condition that increases their risk for deficiency, supplementation should be considered after confirming low serum levels of vitamin E or coagulopathy (elevated prothrombin time and partial thromboplastin time) secondary to vitamin K deficiency.</p><p></p><p class="headingAnchor" id="H1545403080"><span class="h2">Blood pressure and targeted goals</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Office BP</strong> – Office BP measurement should be performed at each supervised health visit. As noted below, strict BP control has shown a beneficial effect on slowing CKD progression in children. (See <a class="local">'Strict blood pressure control'</a> below.)</p><p></p><p class="bulletIndent1">We use the following target BP goals for office measurements for children with CKD  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 8</a>), which are the upper thresholds for normal BP for pediatric patients, as defined by the 2017 American Academy of Pediatrics and American Heart Association [<a href="#rid32">32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;13 years of age – Systolic and diastolic BPs &lt;90<sup>th</sup> percentile of normative data for age, sex, and height  (<a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 10</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adolescents ≥13 years of age – BP ≤120/80 mmHg</p><p></p><p class="bulletIndent1">We recommend strict BP control in all children with CKD because aggressive BP control slows the progression of CKD [<a href="#rid33">33</a>]. Treatment of hypertension (defined as BP greater than the BP targeted goal on three separate occasions) should be initiated using nonpharmacologic therapy and, if needed, antihypertensive therapy. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory BP monitoring (ABPM)</strong> – In accordance with the American Academy of Pediatrics/American Heart Association guidelines, children with CKD should be evaluated periodically with ABPM to evaluate for the presence of masked hypertension (normal clinic BPs but abnormal ABPM) [<a href="#rid34">34,35</a>]. ABPM is also valuable for optimizing antihypertensive therapy to slow disease progression and reverse organ damage and for diagnosing white coat hypertension (elevated clinic BP but normal ABPM). (See  <a class="medical medical_review" href="/d/html/6124.html" rel="external">"Ambulatory blood pressure monitoring in children"</a>.)</p><p></p><p class="bulletIndent1">If ABPM is performed, we use a target goal of a 24-hour mean arterial BP below the 50<sup>th</sup> percentile for pediatric ABPM normative data based on age  (<a class="graphic graphic_table graphicRef94619 graphicRef94618" href="/d/graphic/94619.html" rel="external">table 11A-B</a>) or height  (<a class="graphic graphic_table graphicRef94617 graphicRef94616" href="/d/graphic/94617.html" rel="external">table 12A-B</a>), as recommended by the KDIGO guideline for management of BP in CKD [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiogram</strong> – We obtain echocardiograms in patients with CKD and elevated BP as these children are at risk for left ventricular hypertrophy (LVH), which is associated with adverse cardiovascular disease [<a href="#rid36">36</a>]. The echocardiogram should be repeated annually in children with CKD, especially for those with uncontrolled hypertension and/or documented end-organ damage. Adiposity in children with CKD is an additional independent risk factor for LVH, especially in girls [<a href="#rid37">37</a>]. Electrocardiography is not recommended for evaluation of LVH in children, as it is not a sensitive tool [<a href="#rid32">32</a>]. The diagnosis of LVH in children is outlined separately. (See  <a class="medical medical_review" href="/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1">If LVH is detected, efforts should be made to improve BP control. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="headingAnchor" id="H1442724417"><span class="h2">Neurodevelopment assessment</span><span class="headingEndMark"> — </span>CKD is associated with impaired neurodevelopment [<a href="#rid38">38</a>]. Commonly reported neurocognitive difficulties include deficits in attention regulation and executive function [<a href="#rid39">39</a>]. As a result, routine health maintenance includes early developmental surveillance and screening to identify children with or at risk for neurodevelopmental delay and formal assessment for older children, especially if they have poor school performance. Assessment should include identifying modifiable risk factors (eg, anemia, poor nutrition, hypertension, and uremia) that can negatively impact neurodevelopmental performance. For patients with impaired neurodevelopmental function, referral to early intervention programs or special educational services may be beneficial [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Neurodevelopmental impairment'</a> and  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a> and  <a class="medical medical_review" href="/d/html/614.html" rel="external">"Specific learning disorders in children: Educational management"</a>.)</p><p class="headingAnchor" id="H3966839071"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing is used to monitor kidney function and detect associated CKD complications. The frequency of assessment is based on the severity of kidney dysfunction  (<a class="graphic graphic_table graphicRef129759" href="/d/graphic/129759.html" rel="external">table 13</a>). Tests include:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine, urea, electrolytes, bicarbonate</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium, phosphorus, alkaline phosphatase</p><p class="bulletIndent1"><span class="glyph">●</span>Albumin</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Indices of iron status (ferritin, iron, total iron-binding capacity)</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting lipid profile</p><p class="bulletIndent1"><span class="glyph">●</span>25-hydroxyvitamin D</p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid hormone</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis and urinary protein-to-creatinine ratio</p><p></p><p class="headingAnchor" id="H598450033"><span class="h2">Immunization</span><span class="headingEndMark"> — </span>Children with CKD should receive all childhood vaccinations, with the caveat that live-attenuated vaccines should <strong>not</strong> be administered to children who are immunosuppressed. As an example, live-attenuated influenza vaccine should not be given to children with nephrotic syndrome or those receiving immunosuppressive therapy post-kidney transplantation [<a href="#rid1">1</a>]. After receiving a live-attenuated vaccine, a mandatory minimum waiting period of four weeks is necessary prior to using immunosuppression for kidney transplantation.</p><p>Management for specific vaccinations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal vaccine should be given to all children with nephrotic syndrome and those with CKD, using protocols for children at high risk of invasive pneumococcal disease. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccination should be provided to all children with CKD or undergoing dialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human papillomavirus vaccine should be given to individuals based on the normal schedule. Limited data have shown a robust and sustained response to human papillomavirus vaccination in children with predialysis CKD and those on dialysis; a less robust response was observed in kidney transplant recipients [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">Varicella vaccine</a> should be given to all children with CKD [<a href="#rid42">42,43</a>]. However, since it is a live attenuated vaccine, it is contraindicated in patients with severe immunocompromise, including children receiving high doses of corticosteroids. It is ideally administered as a two-dose regimen when the child is on low-dose regimen of corticosteroids (eg, less than 2 mg/kg of body weight on alternate days) or off of corticosteroid therapy. (See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Immunocompromised hosts'</a> and  <a class="medical medical_review" href="/d/html/6113.html" rel="external">"Symptomatic management of nephrotic syndrome in children", section on 'Varicella'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis in endemic countries is prevented by the universal administration of the Bacillus Calmette-Guérin vaccine at birth. In some countries with a low incidence of tuberculosis, the vaccine is administered to children with CKD prior to kidney transplantation [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PREVENT OR SLOW PROGRESSION OF KIDNEY DISEASE</span></p><p class="headingAnchor" id="H2869634469"><span class="h2">Treat underlying cause of kidney disease</span><span class="headingEndMark"> — </span>In some cases, identifying and treating the underlying primary kidney disease can prevent or slow the progression of disease. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Correction of obstructive uropathy or high-grade vesicoureteral reflux [<a href="#rid45">45-47</a>]. (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Grades III to V'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive therapy for primary nephrotic syndrome and primary and secondary glomerulonephritis (eg, lupus nephritis). (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Long-term outcome of steroid-sensitive nephrotic syndrome'</a> and  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a> and  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a> and  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Prognosis'</a>.)</p><p></p><p class="headingAnchor" id="H2150933523"><span class="h2">Avoid subsequent kidney injury</span><span class="headingEndMark"> — </span>Episodes of acute kidney injury can result in a faster decline in kidney function in children with CKD [<a href="#rid48">48</a>]. Decreased kidney perfusion or the administration of nephrotoxic agents are two common conditions that may result in further kidney injury in children with CKD.</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid acute episodes of kidney hypoperfusion – A subset of children with CKD have impaired tubular sodium reabsorption (salt losers) and urinary concentrating ability, which increases their risk for hypovolemia and hypoperfusion with minor illnesses. At-risk patients should be identified at the onset of an intercurrent illness associated with hypovolemia or hypotension so that fluid repletion can be provided prior to a significant decrease in kidney blood flow.</p><p></p><p class="bulletIndent1">Kidney hypoperfusion is caused by hypotension (eg, septic shock); administration of drugs that lower the kidney perfusion (such as nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme [ACE] inhibitors, and angiotensin II receptor blockers [ARBs]); and volume depletion from vomiting, diarrhea, diuretic use, burns, major surgeries (eg, cardiac surgery performed on cardiopulmonary bypass, orthopedic spine surgeries), and/or bleeding. (See  <a class="medical medical_review" href="/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Causes of prerenal disease'</a> and  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid nephrotoxic drugs – Common nephrotoxic drugs include nonsteroidal antiinflammatory drugs, diagnostic agents (eg, radiographic contrast materials), aminoglycosides, amphotericin B, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>. The administration of such drugs should be avoided or used with caution in patients with underlying CKD, with the assistance of therapeutic drug level monitoring. When drugs that have a narrow therapeutic index are used and precision in dosing is critical (eg, cisplatinum in bone marrow transplant induction protocol) based on kidney function, measurement of glomerular filtration rate (GFR) should be made using <a class="drug drug_pediatric" data-topicid="111397" href="/d/drug information/111397.html" rel="external">iohexol</a> or one of the radioisotopes (<sup>51</sup>Cr-EDTA, <sup>125</sup>Iothalamate, or <sup>99</sup>Tc-DTPA). In this situation, drug dosing ideally should not be based on an estimated GFR using a regression equation. (See  <a class="medical medical_review" href="/d/html/7214.html" rel="external">"Manifestations of and risk factors for aminoglycoside nephrotoxicity"</a> and  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a> and  <a class="medical medical_review" href="/d/html/7241.html" rel="external">"Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p></p><p class="bulletIndent1">Certain drugs, such as <a class="drug drug_pediatric" data-topicid="13156" href="/d/drug information/13156.html" rel="external">cimetidine</a>, <a class="drug drug_pediatric" data-topicid="12865" href="/d/drug information/12865.html" rel="external">trimethoprim</a>, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, and <a class="drug drug_pediatric" data-topicid="13304" href="/d/drug information/13304.html" rel="external">flucytosine</a>, lead to an elevation in serum creatinine but not blood urea nitrogen, because they interfere with either the tubular secretion of creatinine or the laboratory assay for creatinine [<a href="#rid49">49</a>]. As a result, they do not directly affect kidney function.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Slow progression of chronic kidney disease</span><span class="headingEndMark"> — </span>Reported interventions to slow CKD progression include blood pressure (BP) control, reducing protein excretion, correcting anemia, and maintaining normal 25-hydroxyvitamin D levels [<a href="#rid50">50-52</a>]. However, BP control has been the only intervention that has been shown to have a beneficial effect on slowing CKD progression in children. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Interventions'</a>.)</p><p class="headingAnchor" id="H1645622893"><span class="h3">Strict blood pressure control</span><span class="headingEndMark"> — </span>BP should be strictly controlled to reach targeted BP goals  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 8</a>), including the use of antihypertensive therapy in children with CKD when necessary. Strict BP control reduces the rate of progression of CKD in children [<a href="#rid53">53-55</a>].</p><p>For children who require antihypertensive therapy, our preferred agents are an ACE inhibitor or ARB, consistent with 2017 American Academy of Pediatrics Clinical Practice Guideline for screening and management of high BP in children and adolescents [<a href="#rid32">32</a>]. There is good evidence that these agents are more protective than other antihypertensive drugs in slowing the progression of CKD as they control BP and also decrease proteinuria, even in children with advanced CKD [<a href="#rid32">32,53,54,56-59</a>].</p><p>The management of hypertension in children with CKD is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p class="headingAnchor" id="H2138364589"><span class="h3">Reduction of proteinuria</span><span class="headingEndMark"> — </span>For patients with proteinuria, we also treat with an ACE inhibitor or ARB even if BP is not elevated, because data in patients and animal models suggest that this antiproteinuric treatment may slow CKD progression. (See  <a class="medical medical_review" href="/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Renin-angiotensin blockade'</a>.)</p><p class="headingAnchor" id="H3933526545"><span class="h3">Other interventions with insufficient evidence</span><span class="headingEndMark"> — </span>Additional interventions that have been studied in adults with CKD include dietary protein restriction, lipid-lowering therapy, and correction of acidosis and anemia. However, results are inconclusive with respect to the impact of these interventions on delaying the progression of pediatric CKD.</p><p>In particular, data have not shown a benefit of a low-protein diet on the progression of kidney disease in children [<a href="#rid29">29</a>]. The consensus in pediatric nephrology is to provide children with CKD the age-appropriate recommended daily allowance for protein. (See <a class="local">'Growth and nutrition'</a> above.)</p><p>Hyperuricemia, which is due to decreases in urinary excretion, has been proposed to contribute to CKD progression, in part by decreasing kidney perfusion via stimulation of afferent arteriolar vascular smooth muscle cell proliferation. In addition to adult data that suggest an association between hyperuricemia and progressive CKD, a report from the Chronic Kidney Disease in Children (CKiD) study found that a serum uric acid level &gt;7.5 mg/dL was an independent risk factor for accelerated progression of CKD in children and adolescents [<a href="#rid60">60</a>]. This was followed by longitudinal data from CKiD that provided further evidence of the relationship between elevated uric acid and risk for CKD progression [<a href="#rid61">61</a>]. However, there are no recommendations for intervention or monitoring of serum uric acid in children or adults with CKD. The 2012 KDIGO Guideline acknowledges the growing body of evidence regarding the association of hyperuricemia and CKD but concludes that there is insufficient evidence to warrant intervention to lower serum uric acid to slow the rate of GFR decline among both adult and pediatric patients with CKD [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease", section on 'Hyperuricemia'</a>.)</p><p>Anemia is often linked with progression of CKD. However, its ability to predict the development of kidney failure is not well established. While anemia was found to be a predictor of disease progression in the nonglomerular group of the CKiD study, its impact was not observed in other studies [<a href="#rid50">50,62</a>]. However, it is crucial to manage and correct anemia because it can significantly impact growth, quality of life, and executive functioning of children with CKD [<a href="#rid63">63-65</a>].</p><p>While dyslipidemia is a prevalent issue in CKD patients, the impact of lipid-lowering medications on slowing the progression of CKD remains uncertain [<a href="#rid66">66,67</a>].</p><p>Acidosis has also been identified as a risk factor for progression of CKD [<a href="#rid62">62,68</a>]. Observational cohort studies have suggested that correcting acidosis could potentially reduce the risk of CKD progression [<a href="#rid68">68</a>]. However, to validate these findings, a formal prospective long-term therapy study is required. Acidosis has also been associated with adverse effects on muscle strength, specifically grip strength, as well as lower height Z-scores in children with CKD, highlighting the importance of addressing and managing acidosis [<a href="#rid69">69,70</a>].</p><p class="headingAnchor" id="H417368408"><span class="h1">COMPLICATIONS OF CHRONIC KIDNEY DISEASE</span><span class="headingEndMark"> — </span>Complications due to kidney impairment become more prevalent with decreasing glomerular filtration rate (GFR) in children as CKD advances from stages G3 to G5  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>). They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid and electrolytes abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Mineral and bone disorder (see  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia</p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Growth impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Uremia (decreased clearance of substances excreted by the kidneys), potentially causing uremic bleeding or uremic pericarditis</p><p></p><p>These complications and their management are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications"</a>.)</p><p class="headingAnchor" id="H859624595"><span class="h1">PREPARATION FOR KIDNEY FAILURE</span><span class="headingEndMark"> — </span>In children with CKD, kidney replacement therapy (KRT) will generally be needed when the glomerular filtration rate (GFR) falls below 15 mL/min per 1.73 m² (stage G5 CKD, kidney failure) and, in some circumstances, prior to that. Thus, once the estimated GFR declines to &lt;30 mL/min per 1.73 m² (stage G4), it is time to start preparing the child and family for KRT [<a href="#rid4">4</a>]. They should be provided information related to the timing and choice of KRT (preemptive kidney transplantation, peritoneal dialysis, and hemodialysis). The timing and choice of KRT for children are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease"</a>.)</p><p>Rarely, parents or guardians of a child with stage G5 CKD choose conservative management and death over a lifetime of dialysis and transplantation for their child. This should be considered a choice that may, on occasion, be medically, ethically, and legally acceptable. A host of factors need to be considered by the family, clinicians, and, often, the institution's ethics committee. When a decision to forego KRT is deemed acceptable, the family should be supported emotionally and provided with whatever care is necessary to maintain the child in a pain-free state [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/1919.html" rel="external">"Kidney palliative care: Principles, benefits, and core components"</a> and  <a class="medical medical_review" href="/d/html/1877.html" rel="external">"Kidney palliative care: Withdrawal of dialysis"</a>.)</p><p class="headingAnchor" id="H806738550"><span class="h1">LONG-TERM OUTCOME</span></p><p class="headingAnchor" id="H60303484"><span class="h2">Kidney failure</span></p><p class="headingAnchor" id="H859624610"><span class="h3">Pediatric mortality</span><span class="headingEndMark"> — </span>Children with kidney failure (previously referred to as end-stage kidney disease) have a shortened life expectancy compared with children without CKD. Kidney transplantation remains the treatment of choice to maximize survival, growth, and development. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease", section on 'Preemptive transplantation as preferred kidney replacement therapy modality'</a>.)</p><p>Almost three-quarters of children diagnosed with kidney failure in the United States undergo dialysis, and the mortality rate for these children is reported to be at least 30 times higher than in the general pediatric population [<a href="#rid72">72</a>]. However, mortality rates for children receiving chronic dialysis have decreased over time, as shown by data from the United States Renal Data System (USRDS) and the North American Pediatric Renal Trials and Collaborative Studies database [<a href="#rid73">73-75</a>]. The USRDS Annual Data Report, which includes all children who receive kidney replacement therapy (KRT; both kidney transplant and dialysis), found that the one-year adjusted all-cause mortality decreased from 49 per 1000 patient years in 2006-2010 to 39 per 1000 patient years in 2011-2015 [<a href="#rid76">76</a>]. Additional improvement was noted in the 2022 USRDS annual report, especially for the youngest age group (&lt;1 year) [<a href="#rid77">77</a>]. Similarly, survival of infants who initiate peritoneal dialysis during the first year of life has improved substantially since the turn of the century [<a href="#rid78">78,79</a>].</p><p>The leading causes of death are cardiovascular disease and infection. The authors speculate that the reduction in mortality is probably due to improved predialysis care, advances in dialysis technology, and increased clinical experience in caring for these patients.</p><p class="headingAnchor" id="H216174832"><span class="h3">Adulthood outcome</span><span class="headingEndMark"> — </span>Patients placed on KRT before 15 years of age have a greater mortality and morbidity risk than age-matched controls. This was illustrated in a long-term Dutch follow-up study (median time 25.5 years) that observed 30 times greater mortality risk for adults who began pediatric KRT (median time of KRT 25.5 years) than age-matched peers [<a href="#rid80">80</a>]. These individuals were more likely to have motor disabilities, skin cancer, and severe fatigue when they were &gt;40 years old.</p><p class="headingAnchor" id="H31"><span class="h1">QUALITY OF LIFE</span><span class="headingEndMark"> — </span>CKD, as is true for any chronic condition, impacts the quality of life for both the child and family [<a href="#rid16">16,81-84</a>]. In particular, psychological (eg, depression) and social stresses are found in children with CKD and their families [<a href="#rid83">83,84</a>]. The normal progression of the child to independence is impeded, and concerns about body composition and image are greatly magnified in children whose growth and pubertal development are delayed or altered, especially those who undergo chronic dialysis [<a href="#rid83">83</a>]. The prospect of a lifetime with kidney replacement therapy (KRT; dialysis and/or transplant) and the potential for catastrophic complications and/or death makes it difficult to achieve normal childhood and adolescent developmental goals.</p><p>This difficulty continues into adulthood. Compared with age-matched population normative data, patients who had renal failure were more likely to be unemployed and to have lower income and scores on quality-of-life surveys [<a href="#rid85">85-88</a>]. Whereas many adults with childhood kidney failure are able to attain social autonomy, employment remains challenging due to an inability to work because of medical issues and because teachers and employers often fail to recognize and make accommodations for the medical burden of CKD/dialysis [<a href="#rid88">88,89</a>]. This results in loss of self-esteem, social isolation, fatigue, and low mood [<a href="#rid88">88</a>]. These issues were emphasized in an assessment of patient-reported outcomes in pediatric CKD patients and their parents [<a href="#rid90">90</a>].</p><p>The negative impact of chronic disease on the emotional status of the patient's siblings is also well recognized [<a href="#rid91">91</a>]. These siblings frequently feel "neglected" because the parents must provide substantial physical and psychological support to the sick child. Furthermore, the well child may simultaneously feel jealous of the attention provided to the sick child, as well as guilt about being well while the sibling is severely ill.</p><p>Optimal comprehensive management of these issues involves a multidisciplinary approach that proactively addresses these concerns. Key members of the team include social workers and mental health specialists.</p><p class="headingAnchor" id="H2957978822"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H248877635"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15405.html" rel="external">"Patient education: Chronic kidney disease (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86002.html" rel="external">"Patient education: Medicines for chronic kidney disease (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86001.html" rel="external">"Patient education: Bone problems caused by kidney disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The general management of children with chronic kidney disease (CKD) evolves with the stage of CKD  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) and includes routine health maintenance, measures to prevent or slow progression of CKD, treatment of the complications associated with CKD, and identifying and preparing patients with advancing CKD and their families for kidney replacement therapy (KRT). (See <a class="local">'Management approach by stage of chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine health maintenance</strong> – In addition to care provided to all children, routine health maintenance for children with CKD requires more intense monitoring of kidney function and potential complications  (<a class="graphic graphic_table graphicRef129759" href="/d/graphic/129759.html" rel="external">table 13</a>), neurodevelopment, blood pressure (BP) control, and immunization. (See <a class="local">'Routine health maintenance'</a> above.)</p><p></p><p class="bulletIndent1">Growth and nutrition should be monitored closely, with dietary counseling and supplements if needed  (<a class="graphic graphic_table graphicRef52366" href="/d/graphic/52366.html" rel="external">table 3</a>). Initial targets for energy intake are similar to those for healthy children, but children with CKD and growth failure may require higher energy intakes. We suggest that children with CKD be given a daily diet containing at least 100 percent of the dietary reference intake (DRI) for protein based on age and sex  (<a class="graphic graphic_table graphicRef81506" href="/d/graphic/81506.html" rel="external">table 5</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). There is <strong>no</strong> evidence that a low-protein diet slows the progression of kidney disease, and such a diet might impair growth. (See <a class="local">'Growth and nutrition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures to slow progression of CKD</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treat the underlying primary kidney disease if possible. (See <a class="local">'Treat underlying cause of kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevent further kidney injury by avoiding episodes of decreased kidney perfusion or the administration of nephrotoxic agents. (See <a class="local">'Avoid subsequent kidney injury'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintain strict BP control. This has been the only intervention shown to slow the progression of kidney disease in children. In children with CKD, we suggest that BP be strictly controlled to reach targeted BP goals, including through the use of antihypertensive therapy if needed  (<a class="graphic graphic_table graphicRef129760" href="/d/graphic/129760.html" rel="external">table 8</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For children with CKD who require antihypertensive therapy, we suggest an agent that blocks the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitors and angiotensin II receptor blockers [ARBs]) versus other classes of antihypertensive drugs (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Strict blood pressure control'</a> above and <a class="local">'Blood pressure and targeted goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications due to kidney impairment become more prevalent as CKD progresses (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications"</a>). They include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fluid and electrolytes abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Mineral and bone disorder (see  <a class="medical medical_review" href="/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Dyslipidemia</p><p class="bulletIndent2"><span class="glyph">•</span>Endocrine abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Growth impairment</p><p class="bulletIndent2"><span class="glyph">•</span>Uremia including uremic pericarditis and bleeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>KRT</strong> – Preparations for the child and family are initiated for KRT when the estimated glomerular filtration rate (GFR) declines to less than 30 mL/min per 1.73 m<sup>2</sup> (stage G4 CKD). The patient (if appropriate) and family should be provided with information related to timing and choice of KRT (preemptive kidney transplantation, peritoneal dialysis, and hemodialysis). (See <a class="local">'Preparation for kidney failure'</a> above.)</p><p></p><p class="bulletIndent1">For children with kidney failure (stage G5), there is a significant increased risk for morbidity and mortality that persists through adulthood. (See <a class="local">'Long-term outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial considerations</strong> – CKD impacts on the quality of life for both the child and family and includes psychological (eg, depression) and social stresses for both. Comprehensive management of these issues involves a multidisciplinary approach that proactively addresses these concerns. (See <a class="local">'Quality of life'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 2020; 97:1117.</a></li><li><a class="nounderline abstract_t">Pierce CB, Muñoz A, Ng DK, et al. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int 2021; 99:948.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">K/DOQI Clinical practice guidelines for Bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46:S12.</a></li><li><a class="nounderline abstract_t">Foster BJ, Leonard MB. Measuring nutritional status in children with chronic kidney disease. Am J Clin Nutr 2004; 80:801.</a></li><li><a class="nounderline abstract_t">Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.</a></li><li><a class="nounderline abstract_t">Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.</a></li><li class="breakAll">Greenbaum L, Schaefer FS. Pediatric dialysis. In: Pediatric Dialysis, Warady, BA (Eds), Kluwer Academic Publishers, 2004. p.177.</li><li><a class="nounderline abstract_t">K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.</a></li><li><a class="nounderline abstract_t">Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41:I.</a></li><li><a class="nounderline abstract_t">KDOQI, National Kidney Foundation. III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 2006; 47:S86.</a></li><li><a class="nounderline abstract_t">Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151.</a></li><li><a class="nounderline abstract_t">Bacchetta J, Schmitt CP, Bakkaloglu SA, et al. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2023; 38:3163.</a></li><li><a class="nounderline abstract_t">Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 2019; 15:577.</a></li><li><a class="nounderline abstract_t">Ayestaran FW, Schneider MF, Kaskel FJ, et al. Perceived appetite and clinical outcomes in children with chronic kidney disease. Pediatr Nephrol 2016; 31:1121.</a></li><li><a class="nounderline abstract_t">Chen W, Ducharme-Smith K, Davis L, et al. Dietary sources of energy and nutrient intake among children and adolescents with chronic kidney disease. Pediatr Nephrol 2017; 32:1233.</a></li><li><a class="nounderline abstract_t">Sgambat K, Matheson MB, Hooper SR, et al. Prevalence and outcomes of fragility: a frailty-inflammation phenotype in children with chronic kidney disease. Pediatr Nephrol 2019; 34:2563.</a></li><li><a class="nounderline abstract_t">Ku E, Kopple JD, McCulloch CE, et al. Associations Between Weight Loss, Kidney Function Decline, and Risk of ESRD in the Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis 2018; 71:648.</a></li><li><a class="nounderline abstract_t">KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11.</a></li><li><a class="nounderline abstract_t">Shaw V, Polderman N, Renken-Terhaerdt J, et al. Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020; 35:519.</a></li><li><a class="nounderline abstract_t">Rees L, Shaw V, Qizalbash L, et al. Delivery of a nutritional prescription by enteral tube feeding in children with chronic kidney disease stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2021; 36:187.</a></li><li><a class="nounderline abstract_t">McAlister L, Pugh P, Greenbaum L, et al. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020; 35:501.</a></li><li><a class="nounderline abstract_t">Nelms CL, Shaw V, Greenbaum LA, et al. Assessment of nutritional status in children with kidney diseases-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2021; 36:995.</a></li><li><a class="nounderline abstract_t">Stabouli S, Polderman N, Nelms CL, et al. Assessment and management of obesity and metabolic syndrome in children with CKD stages 2-5 on dialysis and after kidney transplantation-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2022; 37:1.</a></li><li><a class="nounderline abstract_t">Desloovere A, Renken-Terhaerdt J, Tuokkola J, et al. The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2021; 36:1331.</a></li><li><a class="nounderline abstract_t">Shaw V, Anderson C, Desloovere A, et al. Nutritional management of the infant with chronic kidney disease stages 2-5 and on dialysis. Pediatr Nephrol 2023; 38:87.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure: 2008 Update. Am J Kidney Dis 2009; 53:S1.</a></li><li><a class="nounderline abstract_t">Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117.</a></li><li><a class="nounderline abstract_t">Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev 2007; :CD006863.</a></li><li><a class="nounderline abstract_t">Uauy RD, Hogg RJ, Brewer ED, et al. Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 1994; 8:45.</a></li><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Douglas CE, Roem J, Flynn JT, et al. Effect of Age on Hypertension Recognition in Children With Chronic Kidney Disease: A Report From the Chronic Kidney Disease in Children Study. Hypertension 2023; 80:1048.</a></li><li><a class="nounderline abstract_t">Flynn JT, Urbina EM, Brady TM, et al. Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association. Hypertension 2022; 79:e114.</a></li><li><a class="nounderline abstract_t">Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99:559.</a></li><li><a class="nounderline abstract_t">Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21:137.</a></li><li><a class="nounderline abstract_t">Brady TM, Roem J, Cox C, et al. Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis 2020; 76:166.</a></li><li><a class="nounderline abstract_t">Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:1824.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Harshman LA. Neurocognition in Pediatric Chronic Kidney Disease: A Review of Data From the Chronic Kidney Disease in Children (CKiD) Study. Semin Nephrol 2021; 41:446.</a></li><li><a class="nounderline abstract_t">Nelson DR, Neu AM, Abraham A, et al. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD. Clin J Am Soc Nephrol 2016; 11:776.</a></li><li><a class="nounderline abstract_t">Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, et al. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD. Nephrol Dial Transplant 2017; 32:132.</a></li><li><a class="nounderline abstract_t">Furth SL, Hogg RJ, Tarver J, et al. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003; 18:33.</a></li><li><a class="nounderline abstract_t">Fadrowski JJ, Furth SL. Varicella zoster virus: vaccination and implications in children with renal failure. Expert Rev Vaccines 2004; 3:291.</a></li><li><a class="nounderline abstract_t">Bamford A, Dixon G, Klein N, et al. Preventing tuberculosis in paediatric kidney transplant recipients: is there a role for BCG immunisation pre-transplantation in low tuberculosis incidence countries? Pediatr Nephrol 2021; 36:3023.</a></li><li><a class="nounderline abstract_t">Hewitt I, Montini G. Vesicoureteral reflux is it important to find? Pediatr Nephrol 2021; 36:1011.</a></li><li><a class="nounderline abstract_t">Ishikura K, Uemura O, Hamasaki Y, et al. Insignificant impact of VUR on the progression of CKD in children with CAKUT. Pediatr Nephrol 2016; 31:105.</a></li><li><a class="nounderline abstract_t">Bundovska-Kocev S, Kuzmanovska D, Selim G, Georgievska-Ismail L. Predictors of Renal Dysfunction in Adults with Childhood Vesicoureteral Reflux after Long-Term Follow-Up. Open Access Maced J Med Sci 2019; 7:107.</a></li><li><a class="nounderline abstract_t">Melhem N, Rasmussen P, Joyce T, et al. Acute kidney injury in children with chronic kidney disease is associated with faster decline in kidney function. Pediatr Nephrol 2021; 36:1279.</a></li><li><a class="nounderline abstract_t">Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999; 246:247.</a></li><li><a class="nounderline abstract_t">Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015; 65:878.</a></li><li><a class="nounderline abstract_t">Fathallah-Shaykh SA, Flynn JT, Pierce CB, et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol 2015; 10:571.</a></li><li><a class="nounderline abstract_t">Shroff R, Aitkenhead H, Costa N, et al. Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. J Am Soc Nephrol 2016; 27:314.</a></li><li><a class="nounderline abstract_t">ESCAPE Trial Group, Wühl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639.</a></li><li><a class="nounderline abstract_t">Wühl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 2008; 23:705.</a></li><li><a class="nounderline abstract_t">Flynn JT, Carroll MK, Ng DK, et al. Achieved clinic blood pressure level and chronic kidney disease progression in children: a report from the Chronic Kidney Disease in Children cohort. Pediatr Nephrol 2021; 36:1551.</a></li><li><a class="nounderline abstract_t">Franscini LM, Von Vigier RO, Pfister R, et al. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens 2002; 15:1057.</a></li><li><a class="nounderline abstract_t">Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 1988; 112:295.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416.</a></li><li><a class="nounderline abstract_t">van den Belt SM, Heerspink HJL, Kirchner M, et al. Discontinuation of RAAS Inhibition in Children with Advanced CKD. Clin J Am Soc Nephrol 2020; 15:625.</a></li><li><a class="nounderline abstract_t">Rodenbach KE, Schneider MF, Furth SL, et al. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis 2015; 66:984.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Roem JL, Hooper SR, et al. Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents. Pediatr Nephrol 2023; 38:489.</a></li><li><a class="nounderline abstract_t">van Biljon G, Meintjes CJ, Becker PJ, Karusseit VOL. Risk factors for progression of chronic kidney disease: An investigation in prepubertal children. Nephrology (Carlton) 2023; 28:276.</a></li><li><a class="nounderline abstract_t">Akchurin O, Molino AR, Schneider MF, et al. Longitudinal Relationship Between Anemia and Statural Growth Impairment in Children and Adolescents With Nonglomerular CKD: Findings From the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis 2023; 81:457.</a></li><li><a class="nounderline abstract_t">Carlson J, Gerson AC, Matheson MB, et al. A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease. Pediatr Nephrol 2020; 35:1659.</a></li><li><a class="nounderline abstract_t">Singh NS, Johnson RJ, Matheson MB, et al. A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease. Pediatr Nephrol 2023; 38:829.</a></li><li><a class="nounderline abstract_t">Baek HS, Kim SH, Kang HG, et al. Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for Outcomes in patients With Pediatric CKD). Pediatr Nephrol 2020; 35:1455.</a></li><li><a class="nounderline abstract_t">Saland JM, Kupferman JC, Pierce CB, et al. Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD. Clin J Am Soc Nephrol 2019; 14:1711.</a></li><li><a class="nounderline abstract_t">Brown DD, Roem J, Ng DK, et al. Low Serum Bicarbonate and CKD Progression in Children. Clin J Am Soc Nephrol 2020; 15:755.</a></li><li><a class="nounderline abstract_t">Brown DD, Carroll M, Ng DK, et al. Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD. Kidney360 2022; 3:666.</a></li><li><a class="nounderline abstract_t">Hogan J, Schneider MF, Pai R, et al. Grip strength in children with chronic kidney disease. Pediatr Nephrol 2020; 35:891.</a></li><li><a class="nounderline abstract_t">Cohen C. Ethical and legal considerations in the care of the infant with end-stage renal disease whose parents elect conservative therapy. An American perspective. Pediatr Nephrol 1987; 1:166.</a></li><li><a class="nounderline abstract_t">McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.</a></li><li><a class="nounderline abstract_t">Mitsnefes MM, Laskin BL, Dahhou M, et al. Mortality risk among children initially treated with dialysis for end-stage kidney disease, 1990-2010. JAMA 2013; 309:1921.</a></li><li><a class="nounderline abstract_t">Weaver DJ Jr, Somers MJG, Martz K, Mitsnefes MM. Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry. Pediatr Nephrol 2017; 32:2319.</a></li><li><a class="nounderline abstract_t">Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2018; 71:A7.</a></li><li><a class="nounderline abstract_t">Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2019; 73:A7.</a></li><li><a class="nounderline abstract_t">Johansen KL, Chertow GM, Gilbertson DT, et al. US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2023; 81:A8.</a></li><li><a class="nounderline abstract_t">Carey WA, Martz KL, Warady BA. Outcome of Patients Initiating Chronic Peritoneal Dialysis During the First Year of Life. Pediatrics 2015; 136:e615.</a></li><li><a class="nounderline abstract_t">Sanderson KR, Yu Y, Dai H, et al. Outcomes of infants receiving chronic peritoneal dialysis: an analysis of the USRDS registry. Pediatr Nephrol 2019; 34:155.</a></li><li><a class="nounderline abstract_t">Groothoff JW, Offringa M, Grootenhuis M, Jager KJ. Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study. Nephrol Dial Transplant 2018; 33:552.</a></li><li><a class="nounderline abstract_t">Gerson AC, Wentz A, Abraham AG, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 2010; 125:e349.</a></li><li><a class="nounderline abstract_t">Aggarwal HK, Jain D, Pawar S, Yadav RK. Health-related quality of life in different stages of chronic kidney disease. QJM 2016; 109:711.</a></li><li><a class="nounderline abstract_t">Tjaden L, Tong A, Henning P, et al. Children's experiences of dialysis: a systematic review of qualitative studies. Arch Dis Child 2012; 97:395.</a></li><li><a class="nounderline abstract_t">Kogon AJ, Matheson MB, Flynn JT, et al. Depressive Symptoms in Children with Chronic Kidney Disease. J Pediatr 2016; 168:164.</a></li><li><a class="nounderline abstract_t">Groothoff JW, Grootenhuis MA, Offringa M, et al. Social consequences in adult life of end-stage renal disease in childhood. J Pediatr 2005; 146:512.</a></li><li><a class="nounderline abstract_t">Mekahli D, Ledermann S, Gullett A, Rees L. Evaluation of quality of life by young adult survivors of severe chronic kidney disease in infancy. Pediatr Nephrol 2014; 29:1387.</a></li><li><a class="nounderline abstract_t">Tjaden LA, Vogelzang J, Jager KJ, et al. Long-term quality of life and social outcome of childhood end-stage renal disease. J Pediatr 2014; 165:336.</a></li><li><a class="nounderline abstract_t">Murray PD, Brodermann MH, Gralla J, et al. Academic achievement and employment in young adults with end-stage kidney disease. J Ren Care 2019; 45:29.</a></li><li><a class="nounderline abstract_t">Tjaden LA, Maurice-Stam H, Grootenhuis MA, et al. Impact of Renal Replacement Therapy in Childhood on Long-Term Socioprofessional Outcomes: A 30-year Follow-Up Study. J Pediatr 2016; 171:189.</a></li><li><a class="nounderline abstract_t">Amaral S, Schuchard J, Claes D, et al. Patient-Reported Outcomes Over 24 Months in Pediatric CKD: Findings From the MyKidneyHealth Cohort Study. Am J Kidney Dis 2023; 82:213.</a></li><li><a class="nounderline abstract_t">Stewart DA, Stein A, Forrest GC, Clark DM. Psychosocial adjustment in siblings of children with chronic life-threatening illness: a research note. J Child Psychol Psychiatry 1992; 33:779.</a></li></ol></div><div id="topicVersionRevision">Topic 6085 Version 60.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32409237" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301749" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : K/DOQI Clinical practice guidelines for Bone metabolism and disease in children with chronic kidney disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15447884" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Measuring nutritional status in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895784" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671933" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678669" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : III. Clinical practice recommendations for anemia in chronic kidney disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247644" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36786859" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197263" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26857711" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Perceived appetite and clinical outcomes in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28210840" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dietary sources of energy and nutrient intake among children and adolescents with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375914" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence and outcomes of fragility: a frailty-inflammation phenotype in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29132947" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Associations Between Weight Loss, Kidney Function Decline, and Risk of ESRD in the Chronic Kidney Disease in Children (CKiD) Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231749" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845057" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32728841" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Delivery of a nutritional prescription by enteral tube feeding in children with chronic kidney disease stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667620" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33319327" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Assessment of nutritional status in children with kidney diseases-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34374836" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Assessment and management of obesity and metabolic syndrome in children with CKD stages 2-5 on dialysis and after kidney transplantation-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730284" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35378603" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nutritional management of the infant with chronic kidney disease stages 2-5 and on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : K/DOQI clinical practice guidelines for nutrition in chronic renal failure: 2008 Update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113009" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943919" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Protein restriction for children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142225" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36861464" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of Age on Hypertension Recognition in Children With Chronic Kidney Disease: A Report From the Chronic Kidney Disease in Children Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35603599" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637203" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917781" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Masked hypertension associates with left ventricular hypertrophy in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32389356" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737850" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34916006" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neurocognition in Pediatric Chronic Kidney Disease: A Review of Data From the Chronic Kidney Disease in Children (CKiD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055465" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26932687" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488988" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15176945" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Varicella zoster virus: vaccination and implications in children with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245418" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preventing tuberculosis in paediatric kidney transplant recipients: is there a role for BCG immunisation pre-transplantation in low tuberculosis incidence countries?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32323004" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vesicoureteral reflux is it important to find?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404649" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Insignificant impact of VUR on the progression of CKD in children with CAKUT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30740171" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Predictors of Renal Dysfunction in Adults with Childhood Vesicoureteral Reflux after Long-Term Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108507" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute kidney injury in children with chronic kidney disease is associated with faster decline in kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475992" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25799137" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635034" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Progression of pediatric CKD of nonglomerular origin in the CKiD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26069294" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846849" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Strict blood-pressure control and progression of renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18335252" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Therapeutic strategies to slow chronic kidney disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200315" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Achieved clinic blood pressure level and chronic kidney disease progression in children: a report from the Chronic Kidney Disease in Children cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460701" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2828592" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777562" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253275" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Discontinuation of RAAS Inhibition in Children with Advanced CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209544" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35650320" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36861372" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Risk factors for progression of chronic kidney disease: An investigation in prepubertal children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36481700" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Longitudinal Relationship Between Anemia and Statural Growth Impairment in Children and Adolescents With Nonglomerular CKD: Findings From the Chronic Kidney Disease in Children (CKiD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333284" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A longitudinal analysis of the effect of anemia on health-related quality of life in children with mild-to-moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35861871" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232640" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for Outcomes in patients With Pediatric CKD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712386" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32467307" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Low Serum Bicarbonate and CKD Progression in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35721607" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932960" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Grip strength in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153275" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ethical and legal considerations in the care of the infant with end-stage renal disease whose parents elect conservative therapy. An American perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215481" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term survival of children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645144" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mortality risk among children initially treated with dialysis for end-stage kidney disease, 1990-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28762101" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477157" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798791" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36822739" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304827" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outcome of Patients Initiating Chronic Peritoneal Dialysis During the First Year of Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30141177" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Outcomes of infants receiving chronic peritoneal dialysis: an analysis of the USRDS registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28992218" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083528" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Health-related quality of life of children with mild to moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118872" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Health-related quality of life in different stages of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22399673" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Children's experiences of dialysis: a systematic review of qualitative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26505290" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Depressive Symptoms in Children with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812455" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Social consequences in adult life of end-stage renal disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24609826" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evaluation of quality of life by young adult survivors of severe chronic kidney disease in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837864" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-term quality of life and social outcome of childhood end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30277317" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Academic achievement and employment in young adults with end-stage kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26768838" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Impact of Renal Replacement Therapy in Childhood on Long-Term Socioprofessional Outcomes: A 30-year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36889426" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Patient-Reported Outcomes Over 24 Months in Pediatric CKD: Findings From the MyKidneyHealth Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1601948" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Psychosocial adjustment in siblings of children with chronic life-threatening illness: a research note.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
